Chronic Eye graft-versus-host disease: what happens after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective observational study enrolling up to 340 patients who had an allogeneic stem cell transplant. Patients will undergo evaluations by hematology and ophthalmology teams and report outcomes themselves to understand the incidence, risk factors, and clinical course of chronic ocular GVHD after transplant. The study will track patient-reported outcomes and objective eye assessments over time to characterize the condition in routine clinical practice. No experimental treatments are given in this design; it aims to observe natural history and factors associated with outcomes. Results may help clinicians identify patients at higher risk and inform follow-up strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥14 years, both genders eligible;
* First allogeneic hematopoietic stem cell transplantation;

  * 100 days post-transplantation, with donor hematopoietic stem cell engraftment confirmed;
* The subject or their legally authorized representative has provided full informed consent, signed the informed consent form, and is willing to complete subsequent follow-up visits

Exclusion Criteria:

* Preexisting moderate-to-severe ocular surface disease prior to transplantation;
* Active ocular infection;
* Presence of other ocular conditions that, in the opinion of the ophthalmologist, may significantly affect the diagnosis of chronic ocular graft-versus-host disease, the evaluation of ocular surface parameters, or the completion of long-term follow-up;
* Patients with active hematologic malignancies.

Where it's running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Chuanhe Jiang
• Email: jch12191@rjh.com.cn
• Phone: 0086-021-64370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biobank for ocular complications from cancer therapy

  This study is collecting information and samples from cancer patients to see how their treatment might cause eye problems, helping to better understand and predict these issues.

  Recruiting University of Maryland, Baltimore · Baltimore, Maryland · NCT06874283

• Belumosudil vs Best Available Therapy for chronic graft-versus-host disease

  In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.

  Recruiting at 3 sites Phase 3 Sanofi · Amsterdam and 2 other locations · NCT07771439

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

• Madecassoside tablets plus standard therapy for sclered scl-cGVHD after allo-HSCT

  This study tests whether adding madecassoside tablets to standard therapy can help people with scleral chronic graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07606703

• Post-transplant dental cleaning to prevent chronic graft-versus-host disease

  This will try a dental cleaning about 28 days after an allogeneic stem cell transplant to see if it lowers the chance of chronic graft-versus-host disease in adult transplant recipients.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07535008

• Adrixetinib (Q702) for adults with active chronic graft-versus-host disease.

  This trial will test whether the oral drug Adrixetinib (Q702) is safe and helps adults with moderate or severe active chronic graft-versus-host disease who have not responded to standard treatments.

  Recruiting at 8 sites Phase 1 Qurient Co., Ltd. · Barcelona and 7 other locations · NCT07138196

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.